GF Fund CSI Medical Service ETF (560260)
- 0.895
- +0.004+0.45%
GF Fund CSI Medical Service ETF (560260) News
Over RMB 10 billion in capital has quietly flowed into this sector!
Since mid-June, the global AI memory semiconductor sector has undergone continuous adjustment, yet the innovative pharmaceuticals segment in both the Hong Kong and A-share markets has exhibited a divergent trend. In terms of indices, from the June lows to date, the CSI Innovative Pharmaceuticals Index has risen by more than 33%, the Hang Seng Innovative Pharmaceuticals Index by over 24%, and the All-Share Pharmaceutical Index by more than 20%. Regarding fund flows, as of July 17, over the past month, the 28 innovative pharmaceuticals-themed ETFs across the market have collectively attracted net inflows exceeding RMB 16.2 billion. Among them, Guangfa’s Hang Seng Innovative Pharmaceuticals ETF (513120), the largest ETF in this category, recorded daily trading volumes exceeding
The sector received positive news, with gains in the Biopharmaceutical ETF, Medical Devices ETF, and Healthcare ETF.
Biopharmaceuticals and medical devices rose, with ETFs including Huaan Biopharmaceutical ETF, Bosera CSI Healthcare 50 ETF, China Asset Management (CAM) Biopharmaceutical ETF, CAM Medical Devices ETF, Tianhong Biopharmaceutical ETF, CAM Pharmaceutical ETF, Da Cheng Medical Equipment ETF, E Fund Medical Devices ETF, Penghua Medical Devices ETF, E Fund Healthcare ETF, Fullgoal CSI Healthcare 50 ETF, China Merchants Medical Devices ETF, Cathay Healthcare ETF, GF Pharmaceutical ETF, GF Healthcare ETF, Bosera Hang Seng Tech Innovative Drug ETF, E Fund Medical Devices ETF, Southern Healthcare ETF, Jianxin Innovative Drug ETF, and biopharmaceuticals.
俄罗斯工程院外籍院士、国家863计划机器人专家孙立宁 确认出席医疗机器人峰会!